NeuroSense Therapeutics Ltd.
corporate_fare Company Profile
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for NRSN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for NRSN spans 6-K, F-3/A, 4, 20-F.
Recent high-impact activity:
- NeuroSense Finalizes 1-for-20 Reverse Split, Effective September 14
- NeuroSense Shareholders Approve Reverse Split Up to 1-for-40
- NeuroSense CEO Letter Reveals Financing Delays for Phase 3 PARAGON and Nasdaq Compliance Strategy
- NeuroSense Locks in December 2026 PrimeC NDS Filing After Health Canada Alignment
- NeuroSense Pursues Reverse Split to Avoid Nasdaq Delisting
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for NRSN, detected from its recent SEC filings · based on capital-structure filings through 2026-07-30.
ATM Capacity Reduced to $3.8M · Nasdaq Delisting Risk Disclosed
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
NRSN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.